Back to search
FDAFDA · Food and drugs·Recall number D-0616-2017

Metronidazole Injection, USP, 500 mg/100 mL, Rx only, Manufactured for: Claris Lifesciences Inc. North Brunswick NJ, 08902, By: Claris Injectable Ltd. Gujarat, India, NDC 36000-001-24

Published April 5, 2017 · Recall initiated: March 10, 2017

Summary

FDA records drug Class II recall D-0616-2017, published April 5, 2017 and initiated March 10, 2017. Recalling firm: Claris Lifesciences Inc; Status: Terminated; Reported quantity: 72072 units; Lot: Lot #: A060205; A060209, Exp.Jan 2018. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Claris Lifesciences Inc
Distributor
Nationwide
Lot
Lot #: A060205; A060209, Exp.Jan 2018
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Metronidazole Injection, USP, 500 mg/100 mL, Rx only, Manufactured for: Claris Lifesciences Inc. North Brunswick NJ, 08902, By: Claris Injectable Ltd. Gujarat, India, NDC 36000-001-24 recalled?

Yes. FDA published recall D-0616-2017 on April 5, 2017. Reported hazard: Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product.

What should I do if I have this product?

Voluntary: Firm initiated · Letter